ReviewEndocrinology and metabolism clinics of North America2014
Type 2 diabetes mellitus and hypertension: an update.
Review in Endocrinology and metabolism clinics of North America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
141 citing papers in PubMed, 4 syntheses or guidelines pooled it, 303 citations in OpenAlex.
- Pharmacist interventions to improve hypertension management among patients with diabetes: a systematic review and meta-analysis of randomized controlled trials.BMC health services research · 2025Pooled it
- Suboptimal blood pressure control and its associated factors among people living with diabetes mellitus in sub-Saharan Africa: a systematic review and meta-analysis.Systematic reviews · 2022Pooled it
- Health system readiness for non-communicable diseases at the primary care level: a systematic review.BMJ open · 2022Pooled it
- Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: A systematic review and meta-analysis.Pharmacology research & perspectives · 2020Pooled it
- Serum bicarbonate concentration and the risk of death in type 2 diabetes: the Fremantle Diabetes Study Phase II.Acta diabetologica · 2023Trial
- Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial.Nature medicine · 2021Trial
- Short-term effects of perindopril-amlodipine vs perindopril-indapamide on blood pressure control in sub-Saharan type 2 diabetic individuals newly diagnosed for hypertension: A double-blinded randomized controlled trial.Journal of clinical hypertension (Greenwich, Conn.) · 2019Trial
- Multicomponent Exercise Improves Hemodynamic Parameters and Mobility, but Not Maximal Walking Speed, Transfer Capacity, and Executive Function of Older Type II Diabetic Patients.BioMed research international · 2018Trial
- Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.Cardiovascular diabetology · 2017Trial
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.Diabetes, obesity & metabolism · 2015 · on this mapTrial
- Combined impact of diabetes mellitus and hypertension on acute kidney injury and survival in critically ill patients: a decade of experience from a Jordanian Tertiary Hospital.Future science OA · 2026Article
- Cardiometabolic Multimorbidity and Sympathetic Overactivity: Translational Rationale for Combined Hepatic-Renal Denervation.JACC. Asia · 2026Review
- Reliability and device objectivity in oscillatory blood pressure measurement - a measurement error analysis to inform clinical decision making.BMC cardiovascular disorders · 2026Article
- Partitioned polygenic scores show mechanistic heterogeneity in type 2 diabetes and hypertension comorbidity.Nature communications · 2026Article
- Hemoglobin A1c-systolic blood pressure index as a novel predictor of cardiovascular disease: evidence from three prospective cohorts.Frontiers in endocrinology · 2026Article
- A realist review to understand the complexity of effective management of type 2 diabetes and hypertension.Public health reviews · 2026Review
- Extinguishing the Fire: Treating Pediatric Type 2 Diabetes by Targeting Obesity Treatment.Diabetes care · 2025Review
- Analysis of determinants of pre-diabetes and diabetes among Bangladeshi adults: an application of multinomial logistic regression model.BMC endocrine disorders · 2025Article
- Impact of moderate to vigorous physical activity on systemic vascular resistance in Danish adults with recently diagnosed type 2 diabetes: a cross-sectional study.Journal of human hypertension · 2025Article
- Effect ofMedical sciences (Basel, Switzerland) · 2025Article
81 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Patients with hypertension and type 2 diabetes are at increased risk of cardiovascular and chronic renal disease. Factors involved in the pathogenesis of both hypertension and type 2 diabetes include inappropriate activation of the renin-angiotensin-aldosterone system, oxidative stress, inflammation, impaired insulin-mediated vasodilatation, augmented sympathetic nervous system activation, altered innate and adaptive immunity, and abnormal sodium processing by the kidney. The renin-angiotensin-aldosterone system blockade is a key therapeutic strategy in the treatment of hypertension in type 2 diabetes. Emerging therapies for resistant hypertension as often exists in patients with diabetes, include renal denervation and carotid body denervation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.